In short
Ravulizumab, also known as ALXN1210 or Ultomiris, is a monoclonal antibody being studied in clinical trials for various conditions. These trials aim to evaluate its safety, efficacy, and pharmacological properties in treating diseases such as neuromyelitis optica spectrum disorder (NMOSD), paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), and COVID-19-related complications. The drug works by inhibiting the complement system, a part of the immune system, and is administered intravenously or subcutaneously.
At a glance
- Drug Name
- Ravulizumab (also known as ALXN1210, Ultomiris)
- Drug Type
- Monoclonal antibody targeting complement protein C5
- Administration
- Intravenous (IV) infusion, some studies exploring subcutaneous (SC) injection
- Conditions Studied
- NMOSD, PNH, gMG, COVID-19 complications
- Patient Populations
- Adults and pediatric patients (in some trials)
- Primary Outcomes
- Safety, efficacy, pharmacokinetics, pharmacodynamics
- Secondary Outcomes
- Disease-specific scores, quality of life measures, biomarker levels
- Study Designs
- Phase 1-3 trials, open-label, single-arm, and randomized controlled studies
- Duration
- Varies by study, ranging from single-dose to multiple years of treatment
What is Ravulizumab?
Ravulizumab, also known by its brand name Ultomiris or research name ALXN1210, is a medication used to treat several rare blood and neurological disorders. It is a type of drug called a monoclonal antibody, which means it's a laboratory-made protein that mimics the immune system's ability to fight off harmful antigens such as viruses.
What Conditions Does Ravulizumab Treat?
Ravulizumab is approved to treat several conditions:
- Paroxysmal Nocturnal Hemoglobinuria (PNH): This is a rare blood disorder where red blood cells break down earlier than they should.
- Atypical Hemolytic Uremic Syndrome (aHUS): This is a rare condition that causes abnormal blood clots to form in small blood vessels in the kidneys.
- Neuromyelitis Optica Spectrum Disorder (NMOSD): This is a rare neurological condition that affects the optic nerves and spinal cord.
- Generalized Myasthenia Gravis (gMG): This is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles.
How Does Ravulizumab Work?
Ravulizumab works by targeting a specific part of the body's immune system called the complement system. Specifically, it blocks a protein called C5, which is part of the complement system. In the conditions that ravulizumab treats, the complement system is overactive and causes damage to the body's own cells.
By blocking C5, ravulizumab helps to prevent this damage. It causes immediate and sustained inhibition of the terminal complement cascade, which is the part of the complement system that causes the most damage in these conditions.
How is Ravulizumab Administered?
Ravulizumab is typically given as an intravenous (IV) infusion, which means it's delivered directly into your bloodstream through a vein. The dosing schedule depends on your weight and the specific condition being treated:
- You'll usually receive a loading dose on the first day of treatment.
- After that, you'll receive maintenance doses every 4 or 8 weeks, depending on your weight.
- The infusion typically takes several hours to complete.
Researchers are also studying a subcutaneous (under the skin) version of ravulizumab, which could potentially be more convenient for some patients.
Efficacy of Ravulizumab
Clinical trials have shown that ravulizumab is effective in treating the conditions it's approved for. Here are some key findings:
- In PNH, ravulizumab has been shown to reduce the need for blood transfusions and improve symptoms like fatigue.
- In NMOSD, it helps prevent relapses (flare-ups of symptoms) and may slow the progression of disability.
- In gMG, it improves muscle strength and daily functioning.
Safety and Side Effects
Like all medications, ravulizumab can cause side effects. Common side effects may include:
- Headache
- Upper respiratory tract infections
- Diarrhea
- Nausea
- Fever
More serious side effects are possible but less common. These can include serious infections, as ravulizumab affects part of your immune system. Your doctor will monitor you closely for any signs of infection.
Ongoing Research
Researchers continue to study ravulizumab to better understand its effects and explore its potential in treating other conditions. Some areas of ongoing research include:
- Its use in treating children with NMOSD.
- Its effectiveness in Chinese adults with PNH.
- Its potential in treating COVID-19-related complications.
- The development of a subcutaneous version for easier administration.
- Its long-term effects on brain and spinal cord imaging in people with NMOSD.
These ongoing studies help doctors and researchers better understand how to use ravulizumab effectively and safely, and may lead to its approval for treating additional conditions in the future.